Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Soluble factors produced by activated CD4+ T cells modulate EBV latency.

Nagy N, Adori M, Rasul A, Heuts F, Salamon D, Ujvári D, Madapura HS, Leveau B, Klein G, Klein E.

Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1512-7. doi: 10.1073/pnas.1120587109. Epub 2012 Jan 17.

3.
4.

Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.

Wilson AD, Morgan AJ.

J Virol. 2002 May;76(10):5071-81. Erratum in: J Virol 2002 Aug;76(16):8504.

5.

c-Myc and Rel/NF-kappaB are the two master transcriptional systems activated in the latency III program of Epstein-Barr virus-immortalized B cells.

Faumont N, Durand-Panteix S, Schlee M, Grömminger S, Schuhmacher M, Hölzel M, Laux G, Mailhammer R, Rosenwald A, Staudt LM, Bornkamm GW, Feuillard J.

J Virol. 2009 May;83(10):5014-27. doi: 10.1128/JVI.02264-08. Epub 2009 Mar 4.

6.

IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter.

Kis LL, Salamon D, Persson EK, Nagy N, Scheeren FA, Spits H, Klein G, Klein E.

Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):872-7. doi: 10.1073/pnas.0912920107. Epub 2009 Dec 22.

7.

T cells modulate Epstein-Barr virus latency phenotypes during infection of humanized mice.

Heuts F, Rottenberg ME, Salamon D, Rasul E, Adori M, Klein G, Klein E, Nagy N.

J Virol. 2014 Mar;88(6):3235-45. doi: 10.1128/JVI.02885-13. Epub 2014 Jan 3.

8.

CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

Nikiforow S, Bottomly K, Miller G.

J Virol. 2001 Apr;75(8):3740-52.

9.

Interleukin-21 regulates expression of key Epstein-Barr virus oncoproteins, EBNA2 and LMP1, in infected human B cells.

Konforte D, Simard N, Paige CJ.

Virology. 2008 Apr 25;374(1):100-13. doi: 10.1016/j.virol.2007.12.027. Epub 2008 Jan 28.

10.

Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells.

Niedobitek G, Agathanggelou A, Herbst H, Whitehead L, Wright DH, Young LS.

J Pathol. 1997 Jun;182(2):151-9.

PMID:
9274524
11.
12.

Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.

De Leo A, Arena G, Stecca C, Raciti M, Mattia E.

Mol Cancer Res. 2011 Oct;9(10):1346-55. doi: 10.1158/1541-7786.MCR-11-0145. Epub 2011 Aug 19.

14.

Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.

Niller HH, Wolf H, Minarovits J.

Autoimmunity. 2008 May;41(4):298-328. doi: 10.1080/08916930802024772. Review.

PMID:
18432410
16.

Cytolytic CD4(+)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation.

Nikiforow S, Bottomly K, Miller G, Münz C.

J Virol. 2003 Nov;77(22):12088-104.

17.

An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation.

Kaye KM, Izumi KM, Li H, Johannsen E, Davidson D, Longnecker R, Kieff E.

J Virol. 1999 Dec;73(12):10525-30.

18.
19.

The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Lear AL, Rowe M, Kurilla MG, Lee S, Henderson S, Kieff E, Rickinson AB.

J Virol. 1992 Dec;66(12):7461-8.

20.

Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas.

Brink AA, Dukers DF, van den Brule AJ, Oudejans JJ, Middeldorp JM, Meijer CJ, Jiwa M.

J Clin Pathol. 1997 Nov;50(11):911-8.

Supplemental Content

Support Center